环孢素A联合CAG方案治疗中高危低增生性骨髓增生异常综合征疗效分析  

Clinical Effect of Cyclosporin A Combined with CAG Regiment on Moderate-or High-risk Hypoplastic Myelodysplastic Syndrome

作　　者：马清君[1] 冷青[1] 季征[1] 张桂敏[1] 吴音[1] 

机构地区：[1]辽宁省鞍山市中心医院血液科,114001

出　　处：《中国全科医学》2010年第5期529-530,共2页Chinese General Practice

摘　　要：目的分析环孢素A(CsA)联合CAG方案〔粒细胞集落刺激因子(G-CSF)+阿糖胞苷(Ara-C)阿柔比星(ACLA)〕治疗中高危低增生性骨髓增生异常综合征(hypo-MDS)的临床疗效。方法应用CsA联合CAG方案治疗17例中高危hypo-MDS患者,随诊观察有效率及副作用发生情况。结果治疗后有效率为82.4%(14/17),全部患者未发现严重毒副作用。结论CsA联合CAG方案治疗中高危hypo-MDS患者安全、有效,但其长期疗效需进一步观察。Objective To observe the clinical effect of cyclosporin A（CsA） with CAG regiment on moderate-or high-risk hypoplastic myelodysplastic syndrome（hypo-MDS）.Methods Senventeen moderate-or high-risk hypo-MDS patients receiving CsA with CAG regiment treatment were followed up to observe the effectiveness and incidence of adverse reactions.Results The total effective rate of 17 patients was 82.4%（14/17）.No serious side effects were noted.Conclusion The combined CsA and CAG regiment treatment is safe,effective in treatment of moderate-or high-risk hypo-MDS,but its long-term effective rate needs further observation.

关 键 词：环孢素A CAG方案 骨髓增生异常综合征 

分 类 号：R557[医药卫生—血液循环系统疾病]